Evidence mapPaperPMID 34718753Full record

ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2021

Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?

Sophie Liabeuf, Marion Pepin, Casper F M Franssen, Davide Viggiano, Sol Carriazo, Ron T Gansevoort, Loreto Gesualdo, Gaye Hafez, Jolanta Malyszko, Christopher Mayer and 6 more

Erratum issuedOpen access · greenAbstract readReview
In one paragraph

Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 82 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Cholinergic system in patients with chronic kidney disease: cognitive and renal implications.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  14. Article
  15. Review
  16. Review
  17. Uremic Toxins, CKD, and Cognitive Dysfunction.Journal of the American Society of Nephrology : JASN · 2025
    Review
  18. The role of the intestinal microbiome in cognitive decline in patients with kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  19. Genetic and circulating biomarkers of cognitive dysfunction and dementia in CKD.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  20. CONNECT: what has been done and what needs to be done.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 15 institutions in 11 countries.

Sophie LiabeufDepartment of Pharmacology, Amiens University Medical Center, Amiens, France.ORCID 0000-0001-5384-9006
Marion PepinUniversité Paris-Saclay, UVSQ, Inserm, Clinical Epidemiology Team, CESP (Centre de Recherche en Epidémiologie et Santé des Populations), Villejuif, France.
Casper F M FranssenDepartment of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Davide ViggianoDepartment of Nephrology, University of Campania "Luigi Vanvitelli", Naples, Italy.
Sol CarriazoDepartment of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain.ORCID 0000-0002-6697-5279
Ron T GansevoortDepartment of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Loreto GesualdoDepartment of Emergency and Organ Transplantation, University of Bari "Aldo Moro", Bari, Italy.
Gaye HafezDepartment of Pharmacology, Faculty of Pharmacy, Altinbas University, Istanbul, Turkey.ORCID 0000-0002-0837-634X
Jolanta MalyszkoDepartment of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
Christopher MayerCenter for Health and Bioresources, Biomedical Systems, AIT Austrian Institute of Technology, Vienna, Austria.
Dorothea NitschFaculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Alberto OrtizDepartment of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain.ORCID 0000-0002-9805-9523
Vesna PešićFaculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Andrzej WiecekDepartment of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, in Katowice, Katowice, Poland.
Ziad A MassyUniversité Paris-Saclay, UVSQ, Inserm, Clinical Epidemiology Team, CESP (Centre de Recherche en Epidémiologie et Santé des Populations), Villejuif, France.
CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)
Hospital Universitario Fundación Jiménez Díaz · ESUniversity Medical Center Groningen · NLAustrian Institute of Technology · ATInserm · FRAltınbaş University · TRCentre Hospitalier Universitaire Amiens-Picardie · FRMedical University of Warsaw · PLUniversity of Belgrade · RSUniversity of Campania "Luigi Vanvitelli" · ITLondon School of Hygiene & Tropical Medicine · GBMedical University of Silesia · PLResearch and Studies Telecommunications Centre · TNCentre de recherche en Epidémiologie et Santé des Populations · FRCHU Ambroise Paré · BEUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) perturbs the crosstalk with others organs, with the interaction between the kidneys and the heart having been studied most intensively. However, a growing body of data indicates that there is an association between kidney dysfunction and disorders of the central nervous system. In epidemiological studies, CKD is associated with a high prevalence of neurological complications, such as cerebrovascular disorders, movement disorders, cognitive impairment and depression. Along with traditional cardiovascular risk factors (such as diabetes, inflammation, hypertension and dyslipidaemia), non-traditional risk factors related to kidney damage (such as uraemic toxins) may predispose patients with CKD to neurological disorders. There is increasing evidence to show that uraemic toxins, for example indoxyl sulphate, have a neurotoxic effect. A better understanding of factors responsible for the elevated prevalence of neurological disorders among patients with CKD might facilitate the development of novel treatments. Here, we review (i) the potential clinical impact of CKD on cerebrovascular and neurological complications, (ii) the mechanisms underlying the uraemic toxins' putative action (based on pre-clinical and clinical research) and (iii) the potential impact of these findings on patient care.

Indexed as

Cerebrovascular DisordersRenal Insufficiency, ChronicUremiaHumansIndicanUremic ToxinsIndicanUremic ToxinscardiovascularCKDindoxyl sulphatestrokeuraemic toxins

Identifiers

PMID34718753
PMCPMC8713157
OpenAlexW3193808756

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.